Press releases
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
More ▼
Key statistics
On Tuesday, Rigel Pharmaceuticals Inc (RI2A:STU) closed at 0.9785, 46.53% above the 52 week low of 0.6678 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9815 |
---|---|
High | 0.9815 |
Low | 0.9665 |
Bid | 0.969 |
Offer | 1.01 |
Previous close | 0.984 |
Average volume | 0.00 |
---|---|
Shares outstanding | 175.40m |
Free float | 171.71m |
P/E (TTM) | -- |
Market cap | 191.19m USD |
EPS (TTM) | -0.1444 USD |
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼